Cognitive-enhancing activities of the polyprenol preparation Ropren® in gonadectomized β-amyloid (25-35) rat model of Alzheimer's disease

Physiology and Behavior

Volumn 157, Issue , 2016, Pages 55-62

  Fedotova, Julia ^a,b,c   Soultanov, Vagif ^d   Nikitina, Tamara ^b   Roschin, Victor ^e   Ordyan, Natalia ^a   Hritcu, Lucian ^f  

^a PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^c ITMO UNIVERSITY   (Russian Federation)

^d Biotechnology Company   (Australia)

^e SAINT PETERSBURG STATE FOREST TECHNICAL UNIVERSITY   (Russian Federation)

^f ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

Author keywords

Alzheimer's disease; Gonadectomy; Memory; Ropren ; Testosterone; Amyloid (25 35)

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; NOOTROPIC AGENT; POLYPHENOL DERIVATIVE; ROPREN; TESTOSTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); PEPTIDE FRAGMENT; POLYPROPYLENE;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG POTENTIATION; GONADECTOMY; GROOMING; LATENT PERIOD; LOCOMOTION; MALE; MORRIS WATER MAZE TEST; NONHUMAN; OPEN FIELD TEST; PASSIVE AVOIDANCE; PASSIVE AVOIDANCE TEST; PRIORITY JOURNAL; RAT; REARING; TESTOSTERONE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANIMAL; AVOIDANCE BEHAVIOR; BLOOD; CHEMICALLY INDUCED; COGNITION DISORDERS; COGNITIVE THERAPY; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; MAZE TEST; ORCHIECTOMY; PROCEDURES; WISTAR RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; COGNITION DISORDERS; COGNITIVE THERAPY; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; NOOTROPIC AGENTS; ORCHIECTOMY; PEPTIDE FRAGMENTS; POLYPROPYLENES; RATS; RATS, WISTAR; TESTOSTERONE;

EID: 84956699980     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2016.01.035     Document Type: Article

References (62)

1. Salomone S., Caraci F., Leggio G.M., Fedotova J., Drago F. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 2012, 73:504-517.
2. Alzheimer's A. Alzheimer's disease facts and figures. Alzheimers Dement. 2011, 2011(7):208-244.
3. Hebert L.E., Scherr P.A., Bienias J.L., Bennett D.A., Evans D.A. Alzheimer disease in the us population: prevalence estimates using the 2000 census. Arch. Neurol. 2003, 60:1119-1122.
4. Stefanacci R. The costs of Alzheimer's disease and the value of effective therapies. Am. J. Manag. Care 2011, (Suppl. 13):S356-S362.
5. Brookmeyer R., Johnson E., Ziegler-Graham K., Arrighi H.M. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007, 3:186-191.
6. Cummings J., Vinters H., Cole G., Khachaturian Z. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 1(Suppl. 1):S2-17.
7. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
8. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
9. LaFerla F.M., Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol. Med. 2005, 11:170-176.
10. Hogervorst E. Effects of gonadal hormones on cognitive behaviour in elderly men and women. J. Neuroendocrinol. 2013, 25:1182-1195.
11. Marshall K. Introduction to the interaction between gonadal steroids and the central nervous system. Biological Basis of Sex Differences in Psychopharmacology 2011, 1-13. Springer Berlin, Heidelberg. J.C. Neill, J. Kulkarni (Eds.).
12. Hogervorst E., Bandelow S., Combrinck M., Smith A.D. Low free testosterone is an independent risk factor for Alzheimer's disease. Exp. Gerontol. 2004, 39:1633-1639.
13. Short R.A., O'Brien P.C., Graff-Radford N.R., Bowen R.L. Elevated gonadotropin levels in patients with Alzheimer disease. Mayo Clin. Proc. 2001, 76:906-909.
14. Tsolaki M., Grammaticos P., Karanasou C., Balaris V., Kapoukranidou D., Kalpidis I., et al. Serum estradiol, progesterone, testosterone, FSH and LH levels in postmenopausal women with Alzheimer's dementia. Hell. J. Nucl. Med. 2005, 8:39-42.
15. Butchart J., Birch B., Bassily R., Wolfe L., Holmes C. Male sex hormones and systemic inflammation in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2013, 27:153-156.
16. Verdile G., Laws S.M., Henley D., Ames D., Bush A.I., Ellis K.A., et al. Associations between gonadotropins, testosterone and β amyloid in men at risk of Alzheimer's disease. Mol. Psychiatry 2014, 19:69-75.
17. Cherrier M.M., Matsumoto A.M., Amory J.K., Asthana S., Bremner W., Peskind E.R., et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology 2005, 64:2063-2068.
18. Holland J., Bandelow S., Hogervorst E. Testosterone levels and cognition in elderly men: a review. Maturitas 2011, 69:322-337.
19. Lu P.H., Masterman D.A., Mulnard R., Cotman C., Miller B., Yaffe K., et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch. Neurol. 2006, 63:177-185.
20. Pike C., Rosario E., Nguyen T.-V. Androgens, aging, and Alzheimer's disease. Endocrine 2006, 29:233-241.
21. Tan R.S., Pu S.J. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male 2003, 6:13-17.
22. Hogervorst E., Combrinck M., Smith A.D. Testosterone and gonadotropin levels in men with dementia. Neuro. Endocrinol. Lett. 2003, 24:203-208.
23. Moffat S.D., Zondrman A.B., Metter E.J., Kawas C., Blackman M.R., Harman S.M., et al. Free testosterone and risk of Alzheimer's disease in older men. Neurology 2004, 62:188-193.
24. Gouras G.K., Xu H., Gross R.S., Greenfield J.P., Hai B., Wang R., et al. Testosterone reduces neuronal secretion of Alzheimer's β-amyloid peptides. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:1202-1205.
25. Yao M., Nguyen T.-V.V., Rosario E.R., Ramsden M., Pike C.J. Androgens regulate neprilysin expression: role in reducing β-amyloid levels. J. Neurochem. 2008, 105:2477-2488.
26. Almeida T., Papadopoulos N. Progression model of prostate cancer. Tumor Suppressor Genes 2003, 211-222. Humana Press. W. El-Deiry (Ed.).
27. Sabella C., Murphy D., Drummond-Webb J. Endocarditis due to streptococcus mitis with high-level resistance to penicillin and ceftriaxone. JAMA 2001, 285:2195.
28. Gillett M.J., Martins R.N., Clarnette R.M., Chubb S.A., Bruce D.G., Yeap B.B. Relationship between testosterone, sex hormone binding globulin and plasma amyloid beta peptide 40 in older men with subjective memory loss or dementia. J. Alzheimers Dis. 2003, 5:267-269.
29. Rosario E.R., Chang L., Stanczyk F.Z., Pike C.J. Age-related testosterone depletion and the development of Alzheimer disease. J. Am. Med. Assoc. 2004, 292:1431-1432.
30. Ramsden M., Nyborg A.C., Murphy M.P., Chang L., Stanczyk F.Z., Golde T.E., et al. Androgens modulate β-amyloid levels in male rat brain. J. Neurochem. 2003, 87:1052-1055.
31. Pike C.J., Carroll J.C., Rosario E.R., Barron A.M. Protective actions of sex steroid hormones in Alzheimer's disease. Front. Neuroendocrinol. 2009, 30:239-258.
32. Raber J. AR, apoE, and cognitive function. Horm. Behav. 2008, 53:706-715.
33. Rosario E.R., Pike C.J. Androgen regulation of β-amyloid protein and the risk of Alzheimer's disease. Brain Res. Rev. 2008, 57:444-453.
34. Papasozomenos S.C. The heat shock-induced hyperphosphorylation of τ is estrogen-independent and prevented by androgens: implications for Alzheimerdisease. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:6612-6617.
35. Papasozomenos S.C., Shanavas A. Testosterone prevents the heat shock-induced overactivation of glycogen synthase kinase-3β but not of cyclin-dependent kinase 5 and c-Jun NH(2)-terminal kinase and concomitantly abolishes hyperphosphorylation of τ: implications for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1140-1145.
36. Rosario E.R., Carroll J., Pike C.J. Testosterone regulation of Alzheimer-like neuropathology in male 3xTg-AD mice involves both estrogen and androgen pathways. Brain Res. 2010, 1359:281-290.
37. Rinnab L., Gust K., Hautmann R.E., Küfer R. Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth. Urologe A 2009, 48:516-522.
38. Walsh J.P., Kitchens A.C. Testosterone therapy and cardiovascular risk. Trends Cardiovasc Med. 2015, 25:250-257.
39. Davinelli S., Sapere N., Zella D., Bracale R., Intrieri M., Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxidative Med. Cell. Longev. 2012, 2012:386527.
40. Kim H.G., Oh M.S. Herbal medicines for the prevention and treatment of Alzheimer's disease. Curr. Pharm. Des. 2012, 18:57-75.
41. Blogger A.C., Rubens J.P., Roshchin V.I. Harvesting and Utilization of Tree Foliage 1989, Riga IUFRO Project Group.
42. Vasiliev V.N., Roschin V.I., Felece S. Extracting compounds of Picea abies (L.) Karst. Rast. Resursy. 1996, 32:151-180.
43. Bizzarri R., Cerbai B., Signori F., Solaro R., Bergamini E., Tamburini I., et al. New perspectives for (S)-dolichol and (S)-nordolichol synthesis and biological functions. Biogerontology 2003, 4:353-363.
44. Swiezewska E., Danikiewicz W. Polyisoprenoids: structure, biosynthesis and function. Prog. Lipid Res. 2005, 44:235-258.
45. Choi D.-Y., Lee Y.-J., Hong J.T., Lee H.-J. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease. Brain Res. Bull. 2012, 87:144-153.
46. Cui X., Zuo P., Zhang Q., Li X., Hu Y., Long J., et al. Chronic systemic d-galactose exposure induces memory loss, neurodegeneration, and oxidative damage in mice: protective effects of R-alpha-lipoic acid. J. Neurosci. Res. 2006, 83:1584-1590.
47. Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011, 51:1014-1026.
48. Pronin A., Danilov L., Narovlyansky A., Sanin A. Plant polyisoprenoids and control of cholesterol level. Arch. Immunol. Ther. Exp. 2014, 62:31-39.
49. Skorupinska-Tudek K., Wojcik J., Swiezewska E. Polyisoprenoid alcohols - recent results of structural studies. Chem. Rec. 2008, 8:33-45.
50. Fedotova J., Soultanov V., Nikitina T., Roschin V., Ordayn N. Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia. Phytomedicine 2012, 19:451-456.
51. Klementiev B., Novikova T., Novitskaya V., Walmod P.S., Dmytriyeva O., Pakkenberg B., et al. A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Aβ25-35. Neuroscience 2007, 145:209-224.
52. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, London. sixth ed.
53. Fedotova J.O., Hartmann G., Lénárd L., Sapronov N. Effects of 5-HT1A receptor agonist and antagonist on anxiety in intact and ovariectomized female rats. Acta Physiol. Hung. 2004, 91:175-184.
54. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N. Engl. J. Med. 2010, 362:329-344.
55. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2006, 20:S69-S74.
56. Janowsky J.S. Thinking with your gonads: testosterone and cognition. Trends Cogn. Sci. 2006, 10:77-82.
57. Handa R.J., Pak T.R., Kudwa A.E., Lund T.D., Hinds L. An alternate pathway for androgen regulation of brain function: activation of estrogen receptor beta by the metabolite of dihydrotestosterone, 5α-androstane-3β,17β-diol. Horm. Behav. 2008, 53:741-752.
58. Hodosy J., Zelmanová D., Majzúnová M., Filová B., Malinová M., Ostatníková D., et al. The anxiolytic effect of testosterone in the rat is mediated via the androgen receptor. Pharmacol. Biochem. Behav. 2012, 102:191-195.
59. Kerr J.E., Allore R.J., Beck S.G., Handa R.J. Distribution and hormonal regulation of androgen receptor (AR) and AR messenger ribonucleic acid in the rat hippocampus. Endocrinology 1995, 136:3213-3221.
60. Tohgi H., Utsugisawa K., Yamagata M., Yoshimura M. Effects of age on messenger RNA expression of glucocorticoid, thyroid hormone, androgen, and estrogen receptors in postmortem human hippocampus. Brain Res. 1995, 700:245-253.
61. Sarkey S., Azcoitia I., Garcia-Segura L.M., Garcia-Ovejero D., DonCarlos L.L. Classical androgen receptors in non-classical sites in the brain. Horm. Behav. 2008, 53:753-764.
62. Bhasin S., Cunningham G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S., et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2006, 91:1995-2010.